Spotlight
Commentary
Cultural Corner
Psychiatric Practice
Series
News
Job Board
CME/CE
Partners
Editorial
Subscribe
Slideshow
Antipsychotics-To Respond or Not to Respond?
Author(s):
A new study brings us closer to answering why antipsychotics are successful in treating schizophrenia in some patients and not in others.
Non-response to Short-term Antipsychotic Drugs in Schizophrenia
• Many patients with schizophrenia do not respond to antipsychotics, but the epidemiology of this phenomenon is unclear
• Variable definitions of “response” contribute to wide estimates of antipsychotic nonresponse rates
• Therefore, more precise estimates of antipsychotic nonresponse are needed
Related Videos
Cobenfy as an Adjunctive Agent in Schizophrenia: Peter J. Weiden, MD, Shares Insights on the Latest Findings
Medications for Different Domains of Schizophrenia
Educating Patients About Cobenfy for the Treatment of Schizophrenia
Answering 3 Clinical Questions in the Wake of the Removal of the Clozapine REMS Requirement
A Clinical Challenge: Transitioning Patients to Cobenfy
Cognitive Issues in Schizophrenia Remain a Challenge
Reset the Clock on Schizophrenia: SPG302, A Regenerative Treatment
A Welcome Action: Removal of the REMS Requirement for Clozapine
Behind the Steering Wheel of Your Brain: Residual Negative and Cognitive Symptoms in Schizophrenia
LB-102: A New, Novel Drug for Schizophrenia
Related Content
